Literature DB >> 19483633

Fascin expression in uterine smooth muscle tumors.

Mehmet Kefeli1, Levent Yildiz, Fatma Cevik Kaya, Oguz Aydin, Bedri Kandemir.   

Abstract

SUMMARY: The diagnosis of malignant, uncertain malignant potential, and benign uterine smooth muscle tumors is derived from histologic criteria such as tumor cell necrosis, mitotic activity, and cytologic atypia. Morphologically, some variants of leiomyoma can be confused with leiomyosarcoma (LMS). In this study, we compared fascin expression in cases of leiomyoma, leiomyoma variants (LVs), uterine smooth muscle tumor of uncertain malignant potential (STUMP), and LMS, and sought to determine the potential role of fascin in differential diagnosis. Fascin expression was investigated through the immunohistochemistry of paraffin-embedded tissue in 79 cases of uterine smooth muscle tumor including 22 usual leiomyoma, 31 LV, 4 STUMP, and 22 LMS cases. The cases were scored on the basis of staining extent (from 0 to 4) and intensity (from 1 to 3), and were assigned a combined score. Fascin expression was present in 20 of 22 (90.9%) LMS, 2 of 4 (50%) STUMP, 1 of 31 (3.2%) LV, and 1 of 22 (4.5%) usual leiomyoma cases. There was a statistically significant difference in fascin extent and intensity between the LMS and benign groups, but no difference between the LMS and STUMP groups. The results of this study indicate that more distinct fascin expression exists in LMS than in the benign groups. Fascin can serve as a reliable immunohistochemical marker in distinguishing uterine LMS from LVs and usual leiomyoma, and it may usefully be used with histologic criteria in diagnosing problematic cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483633     DOI: 10.1097/PGP.0b013e318195da9f

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Authors:  Mary-Margaret L Allen; Jonathan J Douds; Sharon X Liang; Mohamed M Desouki; Vinita Parkash; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

Authors:  Qing Zhang; Margaux Jenna Kanis; Julianne Ubago; Dachao Liu; Denise M Scholtens; Anna E Strohl; John R Lurain; Shohreh Shahabi; Beihua Kong; Jian-Jun Wei
Journal:  Hum Pathol       Date:  2017-12-16       Impact factor: 3.466

3.  Fascin as a useful marker for cancer-associated fibroblasts in invasive lung adenocarcinoma.

Authors:  Yuko Yamada; Atsushi Kurata; Koji Fujita; Masahiko Kuroda
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

4.  Fascin expression in dendritic cells and tumor epithelium in thymoma and thymic carcinoma.

Authors:  Junichiro Sato; Masachika Fujiwara; Tomohiro Kawakami; Ayumi Sumiishi; Seiji Sakata; Atsuhiko Sakamoto; Atsushi Kurata
Journal:  Oncol Lett       Date:  2011-08-17       Impact factor: 2.967

5.  The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas.

Authors:  Andrej Valkov; Sveinung W Sorbye; Thomas K Kilvaer; Tom Donnem; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

6.  The biology of uterine sarcomas: A review and update.

Authors:  Hiroshi Kobayashi; Chiaki Uekuri; Juria Akasaka; Fuminori Ito; Aiko Shigemitsu; Natsuki Koike; Hiroshi Shigetomi
Journal:  Mol Clin Oncol       Date:  2013-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.